PeopleBio, Inc. (KOSDAQ:304840)
South Korea · Delayed Price · Currency is KRW 1,492.00
-16.00 (-1.06%)
At close: Oct 28, 2025
PeopleBio Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Other Revenue | -0 | -0 | - | - | 0 | - |
| 3,132 | 3,732 | 4,453 | 4,445 | 577.08 | 507.85 | |
Revenue Growth (YoY) | -29.76% | -16.20% | 0.18% | 670.22% | 13.63% | - |
Cost of Revenue | 2,454 | 2,403 | 3,077 | 3,115 | 1,365 | 664.06 |
Gross Profit | 678.28 | 1,329 | 1,376 | 1,330 | -787.66 | -156.2 |
Selling, General & Admin | 6,361 | 8,153 | 10,370 | 8,692 | 3,728 | 2,058 |
Research & Development | 3,060 | 3,457 | 5,160 | 3,390 | 2,119 | 1,891 |
Amortization of Goodwill & Intangibles | 382.3 | 361.71 | 358.16 | 380.16 | 177.95 | 13.88 |
Other Operating Expenses | 241.38 | 269.15 | 277.62 | 176.91 | 130.17 | 52.72 |
Operating Expenses | 10,450 | 12,830 | 16,623 | 13,027 | 6,448 | 4,398 |
Operating Income | -9,772 | -11,501 | -15,248 | -11,697 | -7,236 | -4,554 |
Interest Expense | -1,969 | -1,070 | -2,399 | -2,979 | -1,134 | -24.83 |
Interest & Investment Income | 287.26 | 247.61 | 376.99 | 533.49 | 98.51 | 37.47 |
Earnings From Equity Investments | -739.11 | -947.05 | -934.89 | -835.96 | -380.5 | - |
Currency Exchange Gain (Loss) | -2.12 | 2.54 | -34.87 | 15.67 | -1.9 | 1.91 |
Other Non Operating Income (Expenses) | 2,732 | 1,507 | 2,277 | -58.18 | 3,706 | 149.62 |
EBT Excluding Unusual Items | -9,463 | -11,761 | -15,962 | -15,020 | -4,947 | -4,390 |
Gain (Loss) on Sale of Investments | -433.8 | -433.8 | -395.43 | - | - | - |
Gain (Loss) on Sale of Assets | - | - | - | 17.65 | 5.17 | 6.9 |
Other Unusual Items | - | 20.68 | -1,025 | - | - | - |
Pretax Income | -9,896 | -12,173 | -17,382 | -15,003 | -4,942 | -4,383 |
Earnings From Continuing Operations | -9,896 | -12,173 | -17,382 | -15,003 | -4,942 | -4,383 |
Minority Interest in Earnings | 796.68 | 1,260 | 1,348 | 699.7 | 244.85 | - |
Net Income | -9,099 | -10,913 | -16,035 | -14,303 | -4,697 | -4,383 |
Net Income to Common | -9,099 | -10,913 | -16,035 | -14,303 | -4,697 | -4,383 |
Shares Outstanding (Basic) | 22 | 22 | 17 | 15 | 14 | 12 |
Shares Outstanding (Diluted) | 22 | 22 | 17 | 15 | 16 | 12 |
Shares Change (YoY) | 9.16% | 31.10% | 13.30% | -8.80% | 32.17% | - |
EPS (Basic) | -418.45 | -502.24 | -967.45 | -977.75 | -340.35 | -361.19 |
EPS (Diluted) | -418.99 | -502.24 | -967.45 | -978.00 | -457.08 | -361.19 |
Free Cash Flow | -10,196 | -10,990 | -17,001 | -15,242 | -8,188 | -3,652 |
Free Cash Flow Per Share | -468.91 | -505.76 | -1025.76 | -1041.91 | -510.46 | -300.93 |
Gross Margin | 21.65% | 35.61% | 30.90% | 29.92% | -136.49% | -30.76% |
Operating Margin | -311.99% | -308.22% | -342.42% | -263.16% | -1253.81% | -896.78% |
Profit Margin | -290.51% | -292.46% | -360.10% | -321.79% | -813.94% | -863.09% |
Free Cash Flow Margin | -325.54% | -294.51% | -381.80% | -342.91% | -1418.84% | -719.10% |
EBITDA | -8,047 | -9,809 | -13,683 | -10,415 | -6,501 | -4,270 |
EBITDA Margin | -256.92% | -262.87% | - | -234.32% | - | - |
D&A For EBITDA | 1,725 | 1,692 | 1,565 | 1,282 | 734.08 | 284.48 |
EBIT | -9,772 | -11,501 | -15,248 | -11,697 | -7,236 | -4,554 |
EBIT Margin | - | - | - | -263.16% | - | - |
Advertising Expenses | - | 689.49 | 2,905 | 2,879 | 223.74 | 51.5 |
Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.